Fig. 6.

Stimulation of T cell responses and tumor-infiltrated CTLs elicited by nanovaccine in vivo. To validate the CTL effect generated from CM@CaPyro vaccine, the dosing schedule for mice is the same as that of the therapeutic experiment. The mice were sacrificed on day 14 for spleens and peripheral blood and on day 21 for tumors (n = 3). (A, B) The proportion of CD4⁺and CD8⁺T cells in splenocytes from mice is quantified. The ratio of CD8⁺T cells/CD4⁺T cells in tumor (C) and peripheral blood (D). (E) Representative immuno-fluorescence assay of CD8⁺T cells (red) in B16-OVA melanoma tumors. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.